Migraine Nasal Spray Market Trends

Growth Drivers

• Advancements in drug formulations and delivery technologies: The aspect of treatment efficacy and patient experience due to such factors caters to wider adoption of migraine nasal spray industry internationally. For instance, in July 2025, Aptar Pharma notified that it had launched its Freepod nasal spray pump, which is made with 52% bio-based feedstock, marking its first delivery system using renewable materials globally. Besides, the pump, used with Haleon’s Otrivin brand, combines with a mass balance-produced bottle to achieve 60% circular material content for the full device.
• Increasing preference for non-oral and fast-acting therapies: Since most migraine patients suffer from nausea and vomiting, this can limit the effectiveness of oral medications; therefore, there is a growing preference for rapid-onset treatments. According to an NIH article published in July, there has been a strong patient and physician preference for oral drug delivery platforms, wherein surveys and clinical trials showed that most patients, including those on frequent injections, prefer oral alternatives despite potentially increased dosing frequency.
• Emergence of CGRP antagonist therapies: The introduction and approval of migraine-specific nasal sprays targeting pathways such as the calcitonin gene-related peptide receptor have opened new avenues for effective treatment in this field. In October 2022, Pfizer announced that it had finalized its USD 11.6 billion acquisition of Biohaven Pharmaceuticals, acquiring its breakthrough CGRP portfolio, including NURTEC ODT (rimegepant), a dual-use therapy that is approved for both acute and preventive migraine treatment.

Global Prevalence of Headache Disorders (2021)

Source: WHO

Health Care Costs & Quality of Life in U.S Migraine Patients Vs Non-Migraine Patients from a 2 Year Study

Source: JMCP, 2024

Challenges

• High development costs and regulatory hurdles: This is one of the major challenges in the market, creating hesitation among small-scale manufacturers to make investments in this field. The factors such as substantial investment in research, clinical trials, and regulatory approvals, safety, efficacy, and consistent delivery performance have caused an ultimate delay to exclusive product innovations.